Pasar al contenido principal

CONTEXTO INMUNOLOGICO Y EVOLUCION TUMORAL EN LA LEUCEMIA LINFOBLASTICA DE CELULAS B

PID2021-122185OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lessons from mouse models in the impact of risk factors on the genesis of childhood B-cell leukemia

  • Casado-García, Ana
  • Isidro‑Hernández, Marta
  • Alemán-Arteaga, Silvia
  • Ruiz-Corzo, Belén
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • Sánchez, Lucía
  • Sánchez García, Isidro
  • Vicente-Dueñas, Carolina
B-cell acute lymphoblastic leukemia (B-ALL) stands as the primary contributor to childhood cancer-related mortality on a global scale. The development of the most conventional forms of this disease has been proposed to be conducted by two different steps influenced by different types of risk factors. The first step is led by a genetic insult that is presumably acquired before birth that transforms a healthy cell into a preleukemic one, which is maintained untransformed until the second step takes place. This necessary next step to leukemia development will be triggered by different risk factors to which children are exposed after birth. Murine models that recap the stepwise progression of B-ALL have been instrumental in identifying environmental and genetic factors that contribute to disease risk. Recent evidence from these models has demonstrated that specific environmental risk factors, such as common infections or gut microbiome dysbiosis, induce immune stress, driving the transformation of preleukemic cells, and harboring genetic alterations, into fully transformed leukemic cells. Such models serve as valuable tools for investigating the mechanisms underlying preleukemic events and can aid in the development of preventive approaches for leukemia in child. Here, we discuss the existing knowledge, learned from mouse models, of the impact of genetic and environmental risk factors on childhood B-ALL evolution and how B-ALL prevention could be reached by interfering with preleukemic cells., Research in CV-D group has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI22/00379 and co-funded by the European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF)). Research in IS-G group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE; by RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE; by PID2021-122185OB-I00 MCIU/AEI/FEDER, UE, and by Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, and CSI144P20), by the Fundacion Unoentrecienmil (CUNINA project), and by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC). AC-G (CSI067-18), MI-H (CSI021-19) and BR-C are supported by FSE-Conserjería de Educación de la Junta de Castilla y León 2019, 2020, and 2022 (ESF, European Social Fund) fellowship, respectively. SA-A is supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019-088887). LS is supported by a scholarship from the University of Salamanca co-financed by Banco Santander and ESF., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene–Environment Interactions

  • Cobaleda, César
  • Godley, Lucy A.
  • Nichols, Kim E.
  • Marcin W. Wlodarski
  • Sánchez García, Isidro
The recognition of host genetic factors underlying susceptibility to hematopoietic malignancies has increased greatly over the last decade. Historically, germline predisposition was thought to primarily affect the young. However, emerging data indicate that hematopoietic malignancies that develop in people of all ages across the human lifespan can derive from germline predisposing conditions and are not exclusively observed in younger individuals. The age at which hematopoietic malignancies manifest appears to correlate with distinct underlying biological pathways. Progression from having a deleterious germline variant to being diagnosed with overt malignancy involves complex, multistep gene–environment interactions with key external triggers, such as infection and inflammatory stimuli, driving clonal progression. Understanding the mechanisms by which predisposed clones transform under specific pressures may reveal strategies to better treat and even prevent hematopoietic malignancies from occurring. Recent unbiased genome-wide sequencing studies of children and adults with hematopoietic malignancies have revealed novel genes in which disease-causing variants are of germline origin. This paradigm shift is spearheaded by findings in myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) as well as acute lymphoblastic leukemia, but it also encompasses other cancer types. Although not without challenges, the field of genetic cancer predisposition is advancing quickly, and a better understanding of the genetic basis of hematopoietic malignancies risk affects therapeutic decisions as well as genetic counseling and testing of at-risk family members., Research at C. Cobaleda's laboratory was partially supported by Ministerio de Ciencia e Innovación/AEI/FEDER (PID2021–122787OB-I00) and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-.” Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. L.A. Godley receives funding from NIH/NCI U24CA258118, Edward P. Evans Foundation, NIH/HLHBI via Oregon Health & Science University R01HL155426, Leukemia & Lymphoma Society, NIH/NCI U01CA257666, and RUNX1 Research Program. K. Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC), R01CA241452 from the NCI, R21AI113490 from the National Institute of Allergy and Infectious Diseases, Histiocytosis Association, and Cures within Reach. M.W. Wlodarski receives funding from ALSAC, Edward P. Evans Foundation, and The Vera and Joseph Dresner Foundation. Research in ISG group is partially supported by FEDER and by SAF2015–64420-R MINECO/FEDER, UE; by RTI2018–093314-B-I00 MCIU/AEI/FEDER, UE; by PID2021–122185OB-I00 MCIU/AEI/FEDER, UE; by Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, CSI144P20, and CSI016P23); and by the Fundacion Unoentrecienmil (CUNINA project). C. Cobaleda and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PD-1 Expression Promotes Immune Evasion in B-ALL

  • Casado-García, Ana
  • García-Aguilera, Gonzalo
  • Pozo, Julio
  • Oak, Ninad
  • Barrena, Susana
  • Ruiz-Corzo, Belén
  • Lalchandani, Jaanam
  • Chamorro-Vera, Ana
  • Castillo-Robleda, Ana
  • Soriano, Beatriz
  • Alemán-Arteaga, Silvia
  • Sánchez, Elena G.
  • Martínez-Cano, Jorge
  • López-Álvarez de Neyra, Andrea
  • Somoza-Cotillas, Paula
  • Blanco, Óscar
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • García-Criado, Francisco Javier
  • García-Cenador, Begoña
  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Nichols, Kim E.
  • Orfao, Alberto
  • Ramírez‑Orellana, Manuel
  • Sánchez García, Isidro
[Data Availability Statement] The data presented in this study are openly available in to NCBI’s Sequence Read Archive (SRA) under the BioProject accession number PRJNA1084753. This paper does not report original code. Preprints ID: https://doi.org/10.20944/preprints202505.0386.v1., [Data and Code Availability] Authors confirm that all relevant data are included in the paper and/or its supplemental information files. All data reported in this article are deposited to NCBI’s Sequence Read Archive (SRA) under the BioProject accession number PRJNA1084753. This paper does not report original code., [Background/Objectives:] In children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise “silent” preleukemic cells undergo a malignant transformation while escaping immune control, often through unknown mechanisms., [Methods and Results:] Here, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by Pax5 inactivation in mice and correlating with the time of conversion to leukemia, as a novel marker that favors leukemia evasion. This increase in PD-1 expression is apparent across diverse molecular B-ALL subtypes, both in mice and humans. PD-1 is not required for B-cell leukemogenesis, but, in the absence of PD-1, tumor cells express NK cell inhibitory receptors, highlighting the necessity for leukemic cells to evade the host’s NK immune response in order to exit the bone marrow. PD-1 expression reduces natural antitumor immune responses, but it sensitizes leukemic cells to immune checkpoint blockade strategies in mice and humans. PD-1 targeting confers clinical benefits by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL., [Conclusions:] These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL., This research was funded by: Research at C. Cobaleda’s laboratory was partially supported by Grant PID2021-122787OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU” and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-“. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. Research in C. Vicente-Dueñas group has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI22/00379 and co-funded by the European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF)). K. E. Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC); R01CA241452 from the National Cancer Institute; R21AI113490 from the National Institute of Allergy and Infectious Diseases; Histiocytosis Association; and Cures within Reach. MR research is partially supported by Asociación Pablo Ugarte. Research in ISG group is partially supported by Grant PID2021-122185OB-I00 funded by MICIU/AEI/10.13039/501100011033 and PID2024-155590OB-I00 and by “ERDF/EU”, by Junta de Castilla y León (UIC-017, CSI144P20 and CSI016P23), by the Fundación Científica de la Asociación Española contra el Cáncer (TRNSC247893SÁNC) and by Instituto de Salud Carlos III (ISCIII) (AC24/00021). C. Cobaleda, M. Ramírez and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC) and by the Fundacion Unoentrecienmil (CUNINA project). M. Ramírez and I. Sánchez-García have been supported by the TRANSCAN2023-1858-066–REACTION Project. A. Casado-García was supported by an FSE-Conserjería de Educación de la Junta de Castilla y León 2019 (ESF, European Social Fund) fellowship (CSI067-18) and by Juan de la Cierva 2022 (JDC2022-049078-I). B. Ruiz-Corzo is supported by an FSE-Conserjería de Educación de la Junta de Castilla y León 2022 (ESF, European Social Fund) fellowship (CSI002-22). S. Alemán-Arteaga and A. Lopez-Alvarez de Neyra are supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019-088887) and (PRE2022-103628), respectively. J. Martínez-Cano was supported by a predoctoral fellowship FPI-UAM 2019., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

PD-1 Expression Promotes Immune Evasion in B-ALL

  • Casado-García, Ana
  • García-Aguilera, Gonzalo
  • Pozo, Julio
  • Oak, Ninad
  • Barrena, Susana
  • Ruiz-Corzo, Belén
  • Lalchandani, Jaanam
  • Chamorro-Vera, Ana
  • Castillo-Robleda, Ana
  • Soriano, Beatriz
  • Alemán-Arteaga, Silvia
  • Sánchez, Elena G.
  • Martínez-Cano, Jorge
  • López-Álvarez de Neyra, Andrea
  • Somoza-Cotillas, Paula
  • Blanco, Óscar
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • García-Criado, Francisco Javier
  • García-Cenador, Begoña
  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Nichols, Kim E.
  • Orfao, Alberto
  • Ramírez‑Orellana, Manuel
  • Sánchez García, Isidro
In children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise “silent” preleukemic cells undergo a malignant transformation while escaping immune control, often by unknown mechanisms. Here, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by Pax5 inactivation in mice and correlating with the time of conversion to leukemia, as a novel marker that favors leukemia evasion. This increase in PD-1 expression is apparent across diverse molecular B-ALL subtypes, both in mice and humans. PD-1 is not required for B-cell leukemogenesis but in the absence of PD-1, tumor cells express NK cell inhibitory receptors highlighting the necessity for leukemic cells to evade the host's NK immune response in order to exit the bone marrow. PD-1 expression reduces natural anti-tumor immune responses, but it sensitizes leukemic cells to immune checkpoint blockade strategies in mice and humans. PD-1 targeting confers clinical benefit by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL. These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL., The authors thank all the members of their laboratories for discussion. We also thank the Public Resource of Patient-derived and Expanded Leukemias (PROPEL), https://propel.stjude.cloud, as provider of leukemia xenografts used in this study and the American Lebanese Syrian Associated Charities of St. Jude Children’s Research Hospital. Research at C. Cobaleda's laboratory was partially supported by Grant PID2021-122787OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and by “ERDF/EU”, and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-”. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. Research in C. Vicente-Dueñas group has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI22/00379 and co-funded by the European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF)). K. E. Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC); R01CA241452 from the National Cancer Institute; R21AI113490 from the National Institute of Allergy and Infectious Diseases; Histiocytosis Association; and Cures within Reach. MR research is partially supported by Asociación Pablo Ugarte. Research in ISG group is partially supported by Grant PID2021-122185OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and PID2024-155590OB-I00 and by “ERDF/EU”, by Junta de Castilla y León (UIC-017, CSI144P20, and CSI016P23), by the Fundación Científica de la Asociación Española contra el Cáncer (TRNSC247893SÁNC), and by Instituto de Salud Carlos III (ISCIII) (AC24/00021). C. Cobaleda, M. Ramírez, and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC), and by the Fundacion Unoentrecienmil (CUNINA project). M. Ramírez, and I. Sánchez-García have been supported by the TRANSCAN2023-1858-066 – REACTION Project. A. Casado-García was supported by a FSE-Conserjería de Educación de la Junta de Castilla y León 2019 (ESF, European Social Fund) fellowship (CSI067-18) and by Juan de la Cierva 2022 (JDC2022-049078-I). B. Ruiz-Corzo is supported by a FSE-Conserjería de Educación de la Junta de Castilla y León 2022 (ESF, European Social Fund) fellowship (CSI002-22). S. Alemán-Arteaga and A. Lopez-Alvarez de Neyra are supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019-088887) and (PRE2022-103628), respectively. J. Martínez-Cano was supported by a predoctoral fellowship FPI-UAM 2019. We also thank the Hartwell Center and Dr. Ti-Cheng Chang from the Center for Bioinformatics at SJCRH for their support to the whole genome sequencing and bioinformatic pipelines., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deletion of 9p drives B-ALL through heterozygous inactivation of Pax5 and Cd72 in preleukemic cells

  • Ruiz-Corzo, Belén
  • Casado-García, Ana
  • Oak, Ninad
  • Somoza-Cotillas, Paula
  • López-Álvarez de Neyra, Andrea
  • Martínez-Cano, Jorge
  • Pérez-Pons, Alba
  • Sánchez, Elena G.
  • Blanco, Oscar
  • Blanco, Oscar
  • Alonso-López, Diego
  • De Las Rivas, Javier
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • García Criado, Francisco Javier
  • García Cenador, María Begoña
  • Orfao, Alberto
  • Ramírez-Orellana, Manuel
  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Nichols, Kim E.
  • Sánchez-García, Isidro
The contribution of 9p deletion to B cell acute lymphoblastic leukemia (B-ALL) has remained elusive since its discovery more than 40 years ago. Here we show that loss of CD72 is recurrent in B-ALL cases containing PAX5 deletions, and that Cd72 haploinsufficiency drives B-ALL development in Pax5+/- mice. Mechanistically, Cd72+/-;Pax5+/- precursor B cells exhibited an inflammatory transcriptional profile characterized by a decrease in Myd88 expression, a finding that aligns with our previous studies of B-ALL development in Pax5+/- mice following exposure to immune stressors. These combined genomic analyses and functional models provide compelling evidence that co-deletion of 2 contiguous genes, Pax5 and Cd72, drives B cell leukemogenesis., MICIU/AEI/ 10.13039/501100011033 and ERDF/EU grants PID2021-122185OB-I00 and PID2024-155590OB-I00 (to ISG). Junta de Castilla y León grants UIC-017, CSI144P20, and CSI016P23 (to ISG). Fundacion Unoentrecienmil CUNINA2 project (to ISG). Fundación Científica de la Asociación Española contra el Cáncer (TRNSC247893SÁNC) (to ISG). Instituto de Salud Carlos III (ISCIII) (AC24/00021) (to ISG). Fundación Científica de la Asociación Española contra el Cáncer grant PRYCO211305SANC (to CC, MR, and ISG). “La Caixa” Foundation under the project code LCF/PR/HR25/52450048 (to CC, MR, and ISG). TRANSCAN2023-1858-066 – REACTION Project (to MR and ISG). Research at C. Cobaleda’s laboratory was partially supported by Grant PID2021-122787OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and ERDF/EU grant PID2021-122787OB-I00 (to CC). “Fundación Síndrome de Wolf-Hirschhorn o 4p-” research contract (to CC). “Fundación Ramón Areces” and “Banco de Santander” institutional grants to the Centro de Biología Molecular. Instituto de Salud Carlos III (ISCIII) project PI22/00379 (to CVD). American Lebanese Syrian Associated Charities (ALSAC) (to KEN). National Cancer Institute/NIH grant R01CA241452 (to KEN). National Institute of Allergy and Infectious Diseases Histiocytosis Association Cures within Reach grant R21AI113490 (to KEN). Asociación Pablo Ugarte (to MR). FSE-Conserjería de Educación de la Junta de Castilla y León 2019 (ESF, European Social Fund) fellowship CSI067-18 (to ACG). Juan de la Cierva 2022 grant JDC2022-049078-I (to ACG). FSE-Conserjería de Educación de la Junta de Castilla y León 2022 (ESF, European Social Fund) fellowship CSI002-22 (to BRC). Ayuda para Contratos predoctorales para la formación de doctores (PRE2022-103628) (to ALAN). Universidad Autónoma de Madrid predoctoral fellowship FPI-UAM 2019 (to JMC).